STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 96 filers reported holding STOKE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42 | -62.5% | 10,688 | +1.2% | 0.00% | – |
| Q2 2023 | $112 | -6.7% | 10,566 | -26.6% | 0.00% | – |
| Q1 2023 | $120 | -9.8% | 14,398 | 0.0% | 0.00% | – |
| Q4 2022 | $133 | -99.9% | 14,398 | +0.0% | 0.00% | – |
| Q3 2022 | $185,000 | -2.1% | 14,395 | +0.5% | 0.00% | – |
| Q2 2022 | $189,000 | -37.6% | 14,329 | -0.3% | 0.00% | – |
| Q1 2022 | $303,000 | -11.9% | 14,375 | +0.1% | 0.00% | – |
| Q4 2021 | $344,000 | -18.5% | 14,358 | -13.5% | 0.00% | – |
| Q3 2021 | $422,000 | -24.1% | 16,601 | +0.6% | 0.00% | -100.0% |
| Q2 2021 | $556,000 | +8.4% | 16,507 | +25.1% | 0.00% | 0.0% |
| Q1 2021 | $513,000 | -25.3% | 13,200 | +18.9% | 0.00% | 0.0% |
| Q4 2020 | $687,000 | +84.7% | 11,100 | 0.0% | 0.00% | – |
| Q3 2020 | $372,000 | +40.4% | 11,100 | 0.0% | 0.00% | – |
| Q2 2020 | $265,000 | +20.5% | 11,100 | +15.6% | 0.00% | – |
| Q1 2020 | $220,000 | -19.1% | 9,600 | 0.0% | 0.00% | – |
| Q4 2019 | $272,000 | +32.0% | 9,600 | 0.0% | 0.00% | – |
| Q3 2019 | $206,000 | – | 9,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $9,991,000 | 2.07% |
| RTW INVESTMENTS, LP | 3,644,248 | $122,665,000 | 1.85% |
| Cormorant Asset Management, LP | 1,278,276 | $43,027,000 | 1.46% |
| Redmile Group, LLC | 2,458,558 | $82,755,000 | 1.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 233,135 | $7,847,000 | 0.53% |
| Birchview Capital, LP | 15,000 | $505,000 | 0.30% |
| Perceptive Advisors | 1,343,956 | $45,238,000 | 0.29% |
| GILDER GAGNON HOWE & CO LLC | 1,245,956 | $41,939,000 | 0.21% |
| Artal Group S.A. | 250,000 | $8,415,000 | 0.17% |
| Casdin Capital, LLC | 120,000 | $4,039,000 | 0.10% |